2.1 Participants
Participants in this study were drawn from the first 500 individuals who completed baseline assessments as part of the T1000 project, a naturalistic longitudinal study of 1000 individuals including healthy and treatment-seeking individuals with mood, anxiety, substance use and eating disorders41. The T1000 study was conducted at the Laureate Institute for Brain Research (LIBR) in Tulsa, Oklahoma, United States. Baseline assessments occurred between 1/01/2015 and 12/21/2017. The T1000 project was approved by the Western Institutional Review Board and performed in accordance with the Declaration of Helsinki (ClinicalTrials.gov identifier: NCT02450240, “Latent Structure of Multi-level Assessments and Predictors of Outcomes in Psychiatric Disorders”). Participants provided written informed consent and received compensation for their participation.
Participants were recruited from the Laureate Psychiatric Clinic and Hospital, other local mental health providers, and the general community through radio, online, newspaper, and other media advertisements in Tulsa and the surrounding regions of Oklahoma. Participants were evaluated for Diagnostic and Statistical Manual of Mental Disorders–IV or -V (DSM-4 or 5) diagnoses determined by the Mini International Neuropsychiatric Inventory (MINI)42. All participants in the MDD groups entered the T1000 study with significant depressive symptoms (the Patient Health Questionnaire (PHQ-9) ≥ 1043) and met DSM criteria for a past and/or current MDD diagnosis. See Victor et al and colleagues for complete sample size, demographic and screening measures41.
To determine whether individuals with depression show evidence for altered cellular processing related to interoception, only MDD and HC subjects were included in the present analysis. Our previous study using participants from this sample suggested that there was no statistically significant evidence for blood oxygen level-dependent (BOLD) signal differences between un-medicated MDD and MDD with use of selective serotonin reuptake inhibitors (SSRI) on the VIA task44; therefore, both unmedicated and SSRI-medicated subjects were included in this analysis. MDD subjects taking selective norepinephrine reuptake inhibitors (SNRI), or taking various other antidepressants were excluded from the current analysis. Participants were also excluded if they had inflammation or metabolic related disease (e.g., autoimmune disease, inflammatory bowel disease, or diabetes), or they were taking anti-inflammatory or anti-diabetic drugs. In addition, subjects were excluded if they had poor quality or missing VIA fMRI data. Finally, 41 MDD and 35 HC participants remained for data analysis (see Table 1).
Table 1
Sample Demographics and Clinical Characteristics
Group | MDD (n = 41) Mean (sd) | HC (n = 35) Mean (sd) | p-value |
Age | 34.22 (11.63) | 30.03 (9.85) | .10a |
Sex = Male (%) | 11 (26.8) | 14 (40.0) | .33b |
IPAQ Category (%) | | | .01b |
HEPA Active | 10 (20.4) | 20 (58.8) | |
Minimally Active | 11 (26.8) | 8 (23.5) | |
Inactive | 20 (48.8) | 6 (17.6) | |
IPAQ MET-minutes per week | 3849.07 (4279.15) | 4659.21 (3678.56) | .01a |
Body Mass Index | 30.44 (4.60) | 26.59 (4.90) | < .01a |
PROMIS Depression Score | 63.20 (6.55) | 42.49 (6.61) | < .01a |
Note. MDD = major depressive disorder. HC = healthy control. IPAQ, International Physical Activity Questionnaire; PROMIS, Patient-Reported Outcomes Measurement Information System Depression Score. a Two Sample t-test; bχ2 test. |
The following demographic and clinical ratings were assessed: (1) age, sex, education, employment status, International Physical Activity Questionnaire (IPAQ), and body mass index (BMI) metrics; and (2) the Patient-Reported Outcomes Measurement Information System (PROMIS)45 depression scales.
2.2 Neuronal-enriched EV. See Supplemental Methods. EV Track ID#EV210507.
2.2.1 Blood collection. Venous blood was collected during the baseline assessment in BD Vacutainer EDTA Blood Collection tubes then transported to the University of Oklahoma Integrative Immunology Center (IIC) within two hours of collection. Blood tubes were centrifuged at 1300 x g for 10 minutes (min) at room temperature (RT), plasma was removed, aliquoted, and then stored at −80°C until analysis.
2.2.2 EV separation. EV separation method was adapted from our previous publication (Burrows et al 2022b). Plasma was thawed on ice, then centrifuged at 3,000 x revolutions per minute (rpm) for 15 min. 3.5 microliters (mL) of Purified Thrombin (500 U/mL) (System Biosciences, CA, United States; Catalog # TMEXO-1) was added to 350 mL of plasma to make a final concentration 5 U/mL. After incubating plasma/thrombin for 5 min at RT and centrifuging plasma/thrombin at 10,000 rpm at RT for 5 min, 300 mL of plasma was used for EV separation. Briefly, 76 mL of ExoQuick Exosome Precipitation Solution (System Biosciences, CA, United States; Catalog #EXOQ5A-1) was added to 300 mL of plasma, incubated 30 min on ice, and then centrifuged at 1,500 x g at 4°C for 30 min. After removing supernatants, the pellets were centrifuged at 1,500 x g at 4°C for an additional 5 min to remove all traces of supernatant. EV pellets were re-suspended in 300 mL of 1X phosphate buffered saline (PBS) (Thermo Fisher Scientific, United States; Catalog #AM9625) with Halt protease and EDTA-free phosphatase inhibitor cocktail (Thermo Fisher Scientific, United States; Catalog #78425). Finally, 150 mL of EV were used for immunochemical enrichment, and the remaining EV aliquots were stored at −80°C for future analysis.
2.2.3 NEEV enrichment. EVs were enriched via a magnetic streptavidin bead immunocapture kit targeting the neural adhesion marker, L1CAM (CD171) biotinylated antibody-schematic carton of the NEEV enrichment (see Burrows et al46). This method for enriching NEEVs in blood samples has been validated46-49. The CD171 (L1CAM, neural adhesion protein) marker was used for NEEV enrichment due to its high and relatively specific expression in neurons and low levels of expression in many other cell types47.
2.2.4 Flow Cytometry. Once NEEVs were captured and stabilized, the bead/antibody/EV complex was coupled to the EV marker – CD63 fluorescein isothiocyanate (FITC) and neuronal marker – CD171 Allophycocyanin (APC) fluorescent tags and subsequently analyzed by flow cytometry to confirm EV capture and NEEV enrichment.
2.2.5 Western Blot. EVs, NEEVs, EV-depleted plasma, total EV after enrichment, and cells were denatured directly in a 4X Laemmli sample loading buffer and separated by SDS-PAGE using Mini PROTEAN® TGX™ precast gels (Bio-Rad, Catalog # 4561044). Separated proteins were transferred unto polyvinylidene difluoride (PVDF) membranes using a Trans-Blot® Turbo transfer system (Bio-Rad, Catalog # 1704156). Primary antibodies used include CD171 (1:1000, Invitrogen, Catalog # 13-1719-82), CD81 (1:1000, Santa Cruz, Catalog # SC-166029), Alix (1:1000, Santa Cruz, Catalog # SC-53540), and calnexin (1:1000, Cell Signaling, Catalog # 2679).
2.2.6 Transmembrane electron microscopy (TEM). For EM, EV samples suspended in water were fixed in 2% paraformaldehyde. Fixed samples were absorbed onto formvar coated copper grids for 20 min. Samples were then fixed in 1% glutaraldehyde for 5 min. After being rinsed in distilled water, samples were stained with 2% uranyl acetate for 1 min. Excess liquid was wicked off the grid using filter paper, and grids were stored at room temperature until imaging. Imaging was performed on a Hitachi H7600 microscope equipped with an AMT NanoSprint 1200 camera at the Oklahoma Medical Research Foundation (OMRF) imaging core.
2.2.7 Particle size and concentration analysis. The particle concentration and size of EVs and NEEVs were measured using microfluidic resistive pulse sensing (MRPS) method with the Spectradyne nCS1TM instrument (Spectradyne Particle Analysis, Signal Hill, CA, USA).
2.2.8 miRNA Purification. Qiagen miRNeasy Micro Kit (QIAGEN, United States; Catalog #217084) was used for purification of total RNA including miRNA from EVs and NEEVs according to the manufacturer’s protocol. Small RNA concentration was measured using an Agilent Small RNA Kit (Agilent, United States; Catalog #5067-1548) on a Bioanalyzer 2100 instrument (Agilent, United States). RNA samples were stored at -80°C until sequencing.
2.2.9 miRNA sequencing and data processing. RNA samples were sent to the OMRF Clinical Genomics Center for Next Generation Sequencing (NGS). Briefly, miRNA libraries were generated with a Qiagen QIAseq MiR library preparation kit and NGS was performed on an Illumina NextSeq HO SR75. Raw sequence FASTQ files received from OMRF were imported to the Partek Flow Software for data analysis. Adapters from 3’ end were trimmed from the raw reads after a quality check, bases trimmed from both ends, and then aligned to the human genome hg38 using Bowtie alignment. Next, the aligned reads were quantified against the human miRbase mature microRNAs version 22 and reads from miR genes were normalized and scaled to reads per million for statistical data analysis.
2.3 Immunoassays
Serum interleukin 1 receptor antagonist (IL-1ra) concentrations were measured with Human IL-1ra/IL-1F3 Quantikine ELISA kits (R & D Systems, Minneapolis, USA). Serum TNF and IL-6 concentrations were measured with Proinflammatory Panel 1 Human Kit (Meso Scale Diagnostics, Maryland, USA), and C-reactive protein (CRP) was analyzed with Vascular Injury Panel 1 Human Kit (Meso Scale Diagnostics, Maryland, USA). Human Leptin, Insulin Kit (Meso Scale Diagnostics, Maryland, USA) was used to analyze serum leptin concentrations. All serum samples were tested in duplicate. The intra- and inter-assay coefficients of variation (CV) were 3.1% and 15.6% (IL-1ra), 4.2% and 7.0% (IL-6), 3.1% and 12.1% (TNF-a), 2.5% and 10.0% (CRP), and 6.6% and 8.9% (leptin), respectively.
2.4 Neuroimaging
Each participant completed a structural MRI scan followed by fMRI scanning while performing an interoceptive awareness task.
2.4.1 MRI acquisition
MRI images were acquired on two identical General Electric Discovery MR750 (GE Healthcare, Milwaukee, WI) whole-body 3-Tesla MRI scanners. The structural scan was acquired using a T1-weighted magnetization-prepared rapid gradient-echo (MPRAGE) sequence. Anatomical imaging parameters were repetition time (TR)/echo time (TE) = 5/2.012 ms, field of view (FOV) = 240, 186 axial slices, 0.9 mm slice thickness, 256 x 256 matrix, voxel volume = 0.938 x 0.938 x 0.9 mm3, flip angle = 8°, acceleration factor R = 2, inversion time = 725 ms. A single-shot gradient-recalled echo-planar imaging (EPI) sequence with Sensitivity Encoding (SENSE) depicting BOLD contrast was used for functional scans. Functional imaging parameters were TR/TE = 2000/27 ms, FOV/slice = 240/2.9 mm, 128 x 128 acquisition matrix, 39 axial slices, 180 TRs, flip angle = 78°, SENSE acceleration factor R = 2 in anterior-posterior direction, and voxel volume = 1.875 x 1.875 x 2.9 mm3.
2.4.2 Interoceptive awareness task
The Visceral Interoceptive Attention (VIA) task was comprised of two eight-minute runs, each containing interoceptive and exteroceptive conditions. During the interoceptive conditions, the words “heart” and “stomach” cued participants to attend to sensations from that part of the body. During the exteroception (i.e., control) condition, participants attended to the word “target” as it alternated between black and varying shades of grey. Trials lasted 10 seconds, and half of trials were followed by a 5-second period for participants to rate stimulus intensity (0 = ‘no sensation’ to 6 = ‘extreme sensation’). Each run included 6 trials per condition (intertrial interval range 2.5-12.5 s). The VIA task has been previously shown to be effective at mapping the neural signal associated with interoceptive attention, including in depressed individuals5, 50-54.
2.4.3 fMRI data preprocessing
Single-subject image pre-processing was performed using Analysis of Functional NeuroImages (AFNI) software (http://afni.nimh.nih.gov/afni)55. The anatomical scan was registered to the first volume of the EPI time-course and then aligned to Montreal Neurological Institute (MNI) space via affine transformation, saving the transformation parameters for application to the EPI data. The first three TRs were discarded from each EPI time-course to allow the fMRI signal to reach steady state, followed by despiking; slice-timing correction and co-registration to anatomical volumes. Motion correction and spatial transformation to MNI space of the EPI data were implemented in a single transformation. The EPI data were then smoothed with a 4mm Gaussian full-width at half-max smoothing kernel, and signal intensity normalized to reflect percent signal change from each voxel’s mean intensity across the time-course. All images were resampled to 2 x 2 x 2 mm3 isometric voxels.
2.4.4 Subject-level fMRI imaging analysis
Each subject’s functional imaging data were analyzed using a voxelwise general linear model analysis. Block regressors were convolved with a canonical hemodynamic response function and used to model BOLD responses for heart, stomach, and target conditions. Six motion parameters (three translations and three rotations) were included as nuisance regressors. Censoring was done at the regression step by removing volumes with either a Euclidean norm of the derivatives of the six motion parameters greater than 0.3 mm or greater than 10% outlier voxels, determined by 3dToutcount. Percent signal change during each condition was defined as the estimated beta coefficient from single-subject analysis.
2.5 Statistical analysis
2.5.1 Demographic characteristics and clinical ratings
Independent sample t-tests examined differences between MDD and HC on age, sex, IPAQ exercise MET-minutes per week, BMI, and PROMIS depression. Chi^2 test was used to access sex differences between groups.
2.5.2 NEEV miRNA analysis
Statistical analyses on NEEV miR-93 were conducted in R. Scaled miR-93 data (counts per million) were log-transformed due to their non-Gaussian distributions determined by Shapiro-Wilks tests. Outliers were defined as z = ±3 across subjects and set as missing. Independent sample t-tests were used to assess differences between MDD and HC, as well as between un-medicated and SSRI-medicated MDD subjects. In addition, miR-9, a neuronal cell-specific marker56 was compared between NEEV and EV.
2.5.2 Relationship between NEEV miR-93 expression and inflammatory/metabolic markers
All inflammatory/metabolic markers (IL-1ra, TNF, IL-6, CRP, and leptin) were log-transformed due to their non-Gaussian distributions determined by Shapiro-Wilks tests. Outliers were defined as z = ±3 across subjects and set as missing. Independent t-test was used to test the group difference on IL-1ra, IL-6, and TNF; relationships between NEEV miR-93 expression and IL-1ra, IL-6, and TNF within each group were tested by Pearson’s correlations.
Even after log-transformation, the distributions for CRP and leptin were found to be non-Gaussian; therefore, Spearman’s correlations were used to test their relationships to NEEV miR-93 expression within each group, and group differences on these two markers were tested using Mann-Whitney-Wilcoxon non-parametric tests. ANOVA tests were used to evaluate slope differences between MDD and HC groups.
2.5.4 Group-level fMRI imaging analysis
AFNI’s 3dttest++ was used to assess the whole brain voxel-wise group by NEEV miR-93 interaction on BOLD activation of the interoception versus exteroception contrast. The group statistical map was corrected for multiple comparisons according to our previous neuroimaging approaches with this task (see Supplemental Methods). BOLD activation of the interoception versus exteroception contrast within clusters with significant group*miR-93 effects were extracted for follow-up analyses. Robust regression tested the slope of different relationships between NEEV miR-93 and BOLD for each significant cluster. False Discovery Rate correction for multiple comparisons was used across the resulting tests.